PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFlucytosine
Flucytosine
Ancobon, Flucytosine (flucytosine) is a small molecule pharmaceutical. Flucytosine was first approved as Ancobon on 1982-01-01. It is used to treat aids-related opportunistic infections, aspergillosis, candidiasis, chromoblastomycosis, and cryptococcal meningitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
nervous system diseasesD009422
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Ancobon, Flucytosine (discontinued: Flucytosine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flucytosine
Tradename
Company
Number
Date
Products
ANCOBONBausch Health CompaniesN-017001 RX1982-01-01
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ancobonNew Drug Application2022-02-02
flucytosineANDA2024-12-02
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE21: Flucytosine
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX01: Flucytosine
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFlucytosine
INNflucytosine
Description
Flucytosine is an organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. It has a role as a prodrug. It is an organofluorine compound, a pyrimidone, an aminopyrimidine, a nucleoside analogue and a pyrimidine antifungal drug. It is functionally related to a cytosine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(=O)[nH]cc1F
Identifiers
PDB—
CAS-ID2022-85-7
RxCUI—
ChEMBL IDCHEMBL1463
ChEBI ID5100
PubChem CID3366
DrugBankDB01099
UNII IDD83282DT06 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 10,419 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ancobon, Flucytosine
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
755 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use